| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8734625 | Revista Brasileira de Hematologia e Hemoterapia | 2017 | 6 Pages |
Abstract
The results of this retrospective study show that the response to imatinib treatment (400Â mg/day) of Brazilian patients in the chronic phase of chronic myeloid leukemia is within the expected profile when compared to patients reported in international prospective randomized studies.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Ana Lucia Vieira-Mion, Noemi Farah Pereira, Vaneuza Araujo Moreira Funke, Ricardo Pasquini,